The building block model is a form of public utility regulation that is common in Australia.
 Variants of the building block model are currently used in Australia in the regulation of electricity transmission and distribution, gas transmission and distribution, railways, postal services, urban water and sewerage services, irrigation infrastructure, and port access.
 The Australian Competition and Consumer Commission has stated that it intends to use a version of the building block model to determine indicative access prices for fixed-line telecommunications services.
 The building block model is so-called because the allowed revenue of the regulated firm is equal to the sum of underlying components or building blocks consisting of the return on capital, the return of capital (also known as depreciation), the operating expenditure, and various other components such as taxes and incentive mechanisms.
Eslicarbazepine acetate (trade names Aptiom in the US, Zebinix in Europe, Exalief in Russia), abbreviated as ESL, is an anticonvulsant medication approved for use in Europe and the United States as monotherapy or adjunctive therapy (additional therapy) for partial-onset seizures epilepsy.
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication.
 It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland) and Celontin (United States).
 The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, "N"-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.
Chloroacetyl chloride is a chlorinated acyl chloride.
 It is a bifunctional compound, making it a useful building block chemical.
Retigabine or ezogabine is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.
 The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline.
 It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011.
 Production has been discontinued in June 2017.
2-Bromobutyric acid is an carboxylic acid with the molecular formula CHBrO.
 It is a clear, yellow liquid.
 The 2-position is an asymmetric carbon, so there are two enantiomers of this compound.
 2-Bromobutyric acid is mainly used as a building block chemical, such as in the preparation of Levetiracetam, an anticonvulsant medication.
Levetiracetam, marketed under the trade names Keppra among others, is a medication used to treat epilepsy.
 It is used for partial onset, myoclonic, or tonic-clonic seizures.
 It is the S-enantiomer of etiracetam.
Rufinamide is an anticonvulsant medication.
 It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.
Tiagabine (trade name Gabitril) is an anticonvulsant medication used in the treatment of epilepsy that is produced by Cephalon.
 The drug is also used off-label in the treatment of anxiety disorders and panic disorder.
Ethadione is an anticonvulsant medication in the oxazolidinedione family used mainly to treat seizures.

Question: What is the trade name for the anticonvulsant medication that uses Bromobutyric acid as a building block chemical?
Answer: Keppra